Inactive Instrument

Orchard Therapeutics plc Stock price

Equities

ORTX

US68570P2002

Pharmaceuticals

Dynamic Chart
Orchard Therapeutics Receives FDA Approval of Lenmeldy? (atidarsagene autotemcel) CI
Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome CI
Japanese Shares Skid as Inflation Slows Faster-than-Expected in January MT
Kyowa Kirin Acquires All Outstanding Shares of Orchard Therapeutics MT
Orchard Therapeutics plc Announces Board Changes CI
Orchard Therapeutics Completes Sale to Japan's Kyowa Kirin MT
Orchard Therapeutics plc(NasdaqCM:ORTX) dropped from NASDAQ Composite Index CI
Kyowa Kirin Co., Ltd. completed the acquisition of Orchard Therapeutics plc from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others. CI
Orchard Therapeutics’ Gene Therapy Gets Swiss Regulatory Approval MT
Orchard Therapeutics Receives Swiss Agency for Therapeutic Products Approval for Libmeldy in Early-Onset Metachromatic Leukodystrophy CI
Orchard Therapeutics Gets FDA Fast Track Designation for Enzyme Deficiency Treatment MT
Orchard Therapeutics plc Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH CI
Earnings Flash (ORTX) ORCHARD THERAPEUTICS (EUROPE) LIMITED Posts Q3 Revenue $6.3M MT
Orchard Therapeutics plc Reports Earnings Results for the Third Quarter Ended September 30, 2023 CI
Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-Of-Concept Study of Otl-203 in Mps-Ih At Esgct 2023 CI
More news
Managers TitleAgeSince
Chief Executive Officer 60 14-12-31
President 54 17-12-31
Chief Tech/Sci/R&D Officer - 18-05-31
Members of the board TitleAgeSince
Director/Board Member - Jan. 23
Director/Board Member - Jan. 23
60 -
More insiders
Orchard Therapeutics plc is a gene therapy company. The Company is engaged in transforming the lives of people affected by rare diseases through the development of curative gene therapies. Its ex vivo autologous hematopoietic stem cell (HSC), gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. Its ex vivo autologous HSC gene therapy approach seeks to transform a patient's autologous HSCs into a gene-modified cellular drug product to treat the patient's disease. Its lead program is OTL-200 operates under the brand name Libmeldy for eligible patients with early-onset metachromatic leukodystrophy (MLD). Its programs in immunological disorders consist of two pre-clinical programs, OTL-104 for Crohn's disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2 (NOD2-CD), and OTL-105 for hereditary angioedema (HAE).
More about the company
  1. Stock
  2. Equities
  3. Stock Orchard Therapeutics plc - Nasdaq